Stifel initiated coverage of Smith & Nephew with a rating of Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2025 | Buy → Hold | HSBC Securities | |
| 3/12/2025 | Buy → Neutral | UBS | |
| 11/6/2024 | Buy → Hold | Berenberg | |
| 11/1/2024 | Buy → Hold | Deutsche Bank | |
| 7/24/2024 | Buy | Deutsche Bank | |
| 6/5/2024 | Neutral → Buy | UBS | |
| 11/28/2023 | Underweight → Equal Weight | Barclays | |
| 11/3/2023 | Neutral → Overweight | JP Morgan |
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: Robotics: Optimizing and personalizing surgery With CORIOGRAPH◊ Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System's image-agnostic solution for robotic-assisted knee and computer-guided hip replacement procedures, Smith+Nephew offers a highly personalized approach for both surgeons and their patients. CORIOGRAPH's recent addition of support for hip procedures
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: Spatial Surgery Smith+Nephew continues to pioneer in Sports Medicine and is excited to introduce a new category called Spatial Surgery - a revolutionary new frontier in arthroscopic surgical innovation. This 510(k)-pending technology called the TESSA◊ Spatial Surgery System (Tracking Enabled Spatial Surgery Assistant) plans to combine personalized operative planning with a real-time, trackin
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) highlights the exceptional performance of Smith+Nephew's proprietary OXINIUM on highly cross-linked polyethylene. The data indicates that this combination has the highest survivorship rate (94.1%) among all bearing combinations over a 20-year period for total hip arthroplasty (THA).1 The report on 20-year outcomes corroborates similar findings and peer-reviewed publications from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR).2 Whitehou
SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)
SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)
3 - SMITH & NEPHEW PLC (0000845982) (Reporting)
HSBC Securities downgraded Smith & Nephew from Buy to Hold
UBS downgraded Smith & Nephew from Buy to Neutral
Berenberg downgraded Smith & Nephew from Buy to Hold
New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc
New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra
Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an
STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors. Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM. He recent
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)